Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotechnology sector.
The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.
2025 base-rate subscriptions are $A2,200 a year (including GST in Australia).
Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.
Mesoblast’s late-December Ryoncil success at the US Food and Drug Administration for graft versus host disease helped push the Biotech Daily Top 40 Index (BDI-40) up 6.0 percent to another record cumulative market capitalization high of $23,244 million.
The BDI-40 ended the year up 50.0 percent from the value of the 40 companies at December 31, 2023 and down 8.4 percent compared to last year’s $25,369 million, which included Pro Medicus, recently promoted into the Big Caps (see below).
The ASX200 closed the year up 7.5 percent at 8,159 points, the Nasdaq Biotechnology Index (NBI) slipped 1.4 percent to 4,311 points and the collective market capitalization of the four Big Caps of Cochlear, CSL, Pro Medicus and Resmed (which are not included in the BDI-40) climbed 14.5 percent to $235,442 million.
Pro Medicus was the only Big Cap to climb in December, up 0.8 percent to $26,137 million, but up 159.3 percent for the year to December 31, 2024. Resmed was up 44.3 percent to $53,995 million for the 12 months, with CSL slipping 1.5 percent to $136,343 million and Cochlear down 3.6 percent to $18,967 million.
Eighteen of the Biotech Daily Top 40 Index (BDI-40) companies were up in 2024, 11 by more than 100 percent and 16 by more than 10 percent; with 22 down, of which 16 fell more than 10 percent and five fell more than 50 percent.
Mesoblast was by far the best in 2024, up $3,245 million or 1,046.8 percent to $3,555 million, followed by Syntara up 641.2 percent for the year to $126 million, Orthocell (296.3%), Clarity (168.7%), Opthea (163.8%), Telix (154.5%), Cynata (145.5%), Genetic Signatures (130.6%), Amplia (118.75%), Dimerix (118.4%) and EBR (103.2%).
Percheron led the falls, following its trial of avicursen (ATL1102) for Duchenne muscular dystrophy, down 90 percent in December and 84.9 percent for the year to $8 million, followed by Impedimed (64.2%), Imugene (63.5%), Curvebeam (60.6%), Neuren (50.0%) Starpharma (34.3%), Nanosonics (32.0%), Medical Developments (30.3%), 4D Medical (29.0%), Universal Biosensors (26.2%), Clinuvel (25.4%) and Nova Eye (20.0%).
The 11 companies in Cannabis Corner slipped a further 1.4 percent in December, down 27.1 percent for the year to a cumulative market capitalization of $280 million. Seven fell, three were up and Medlab remained suspended
On the Nasdaq, Protagonist rose 91.5 percent to $3,717 million, in the year to December 31, 2024, but Bionomics lost 55.5 percent to $8 million, followed by Eyepoint (50.4%), Incannex (44.4%) and Kazia (29.4%).
Biotech Daily editor, David Langsam, owns shares in 4D Medical, Acrux, Actinogen, Alcidion, Alterity, Amplia, BTC Health, Clarity, Cochlear, Control Bionics, Cynata, Nanosonics, Neuren, Patrys, Polynovo, Syntara and Telix, as well as non-biotechnology stocks.
Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies.
These holdings are liable to change:
https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/